Teva Pharmaceutical Industries Limited (TEVA) : 17 analysts are covering Teva Pharmaceutical Industries Limited (TEVA) and their average rating on the stock is 1.56, which is read as a Buy. 11 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Teva Pharmaceutical Industries Limited (TEVA) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Teva Pharmaceutical Industries Limited (TEVA) : 15 investment research analysts covering Teva Pharmaceutical Industries Limited (TEVA) have an average price target of $72.26 for the near short term. The highest target price given by the Brokerage Firm to the stock is $100 and the lowest target is $57 for the short term. Analysts expect the variance to be within $10.89 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Oppenheimer upgrades its rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA). The shares have been rated Outperform. Previously, the analysts had a Perform rating on the shares. The rating by the firm was issued on September 2, 2016.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): stock was range-bound between the intraday low of $50.67 and the intraday high of $51.45 after having opened at $51.11 on Wednesdays session. The stock finally closed in the red at $51.11, a loss of -0.08%. The stock remained in the red for the whole trading day. The total traded volume was 5,737,819 shares. The stock failed to cross $51.45 in Wednesdays trading. The stocks closing price on Thursday was $51.33.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.